INPP5D (SHIP1) Inhibition to Shift Microglial Polarization

Target: INPP5D Composite Score: 0.758 Price: $0.69▼9.6% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🔬 Microglial Biology 🧠 Neurodegeneration 🔥 Neuroinflammation

🏆 ChallengeSolve: INPP5D (SHIP1) Inhibition to Shift Microglial Polarization$126K bounty →

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

B+

Composite: 0.758

Top 8% of 1875 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

C Mech. Plausibility 15% 0.42 Top 91%

D Evidence Strength 15% 0.38 Top 82%

B+ Novelty 12% 0.72 Top 37%

F Feasibility 12% 0.22 Top 97%

C Impact 12% 0.48 Top 90%

D Druggability 10% 0.32 Top 90%

D Safety Profile 8% 0.32 Top 92%

C+ Competition 6% 0.55 Top 65%

D Data Availability 5% 0.35 Top 94%

D Reproducibility 5% 0.38 Top 88%

Evidence

8 supporting | 6 opposing

Citation quality: 0%

Debates

3 sessions C+

Avg quality: 0.52

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

TREM2 agonism vs antagonism in DAM microglia

The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

INPP5D (SHIP1) Inhibition to Shift Microglial Polarization starts from the claim that modulating INPP5D within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview INPP5D (SHIP1) Inhibition to Shift Microglial Polarization starts from the claim that modulating INPP5D within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "INPP5D (SHIP1) Inhibition to Shift Microglial Polarization Mechanism of Action INPP5D, also known as SHIP1, is an inositol polyphosphate 5-phosphatase that specifically dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP3) to phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2). This enzymatic activity places INPP5D as a critical negative regulator of the phosphatidylinositol 3-kinase (PI3K) signaling axis in myeloid cells, including microglia. In the resting state, microglial PI3K signaling must be carefully calibrated to maintain homeostasis while permitting rapid response to threats. When activating receptors such as TREM2 engage their ligands, PI3K generates PIP3 at the inner leaflet of the plasma membrane, creating docking sites for pleckstrin homology domain-containing effectors including AKT (protein kinase B). AKT phosphorylation at threonine 308 and serine 473 drives a cascade of pro-survival, anti-apoptotic, and metabolically reprogramming events that are essential for the Disease-Associated Microglia (DAM) transcriptional program. INPP5D counterbalances this process by converting the signaling lipid PIP3 into the less potent PI(3,4)P2, thereby attenuating the magnitude and duration of PI3K/AKT signaling. Selective pharmacological inhibition of INPP5D removes this molecular brake, permitting sustained accumulation of PIP3 following receptor activation. In the context of TREM2 agonism, whether achieved through antibody engagement or endogenous ligand availability, INPP5D inhibition would amplify the downstream PI3K/AKT cascade. This enhanced signaling creates intracellular conditions that favor DAM commitment: increased expression of lipid metabolism genes, upregulation of phagocytic machinery including APOE and LPL, activation of oxidative phosphorylation and glycolytic flexibility, and suppression of pro-inflammatory cytokine production. The synergy between TREM2 agonism and INPP5D inhibition is mechanistically grounded in their convergence on the same lipid second messenger pool, where one receptor provides the input signal and the phosphatase provides the output dampening. Supporting Evidence The supporting evidence establishes INPP5D as a genetically implicated, mechanistically plausible therapeutic target within a defined microglial signaling network. The enrichment of phosphatidylinositol metabolic process genes including CSF1R, INPP5D, and PLCG2 in a gene set with extreme statistical significance (p=3.5e-06, odds ratio 142.4) indicates that this lipid signaling module is biologically constrained and functionally coherent. These three genes operate in the same biochemical pathway: CSF1R is a receptor tyrosine kinase that activates PI3K upon colony-stimulating factor binding, INPP5D terminates PI3K-derived PIP3 signaling, and PLCG2 generates diacylglycerol and inositol trisphosphate from phosphatidylinositol 4,5-bisphosphate, providing orthogonal second messenger generation. The extraordinary odds ratio suggests that perturbation of this pathway is highly enriched in disease-relevant contexts, likely reflecting the central role of microglial lipid signaling in neurodegeneration. The genetic association between INPP5D and Alzheimer's disease through microglial signaling networks provides independent corroboration that naturally occurring genetic variation in this gene influences disease risk in humans. This evidence is particularly compelling because it derives from human genetics rather than preclinical models, reducing concerns about species differences in microglial biology. Common and rare variants in INPP5D may confer either protective or risk-conferring effects by subtly altering enzyme expression or catalytic activity, thereby modulating the set point of PI3K signaling in brain microglia throughout life. The documented role of INPP5D in modulating the PI3K/AKT pathway downstream of multiple myeloid receptors establishes the molecular mechanism through which genetic variation could influence disease trajectories. Clinical Relevance The clinical imperative for interventions targeting microglial dysfunction in Alzheimer's disease is substantial and well-documented. Microglia in the aged and Alzheimer's brain adopt a spectrum of activation states, with the neurotoxic microglia that drive synaptic loss and neuronal death representing the dominant population in many patients. The DAM program, by contrast, represents a homeostatic or even beneficial microglial response to amyloid and tau pathology that promotes debris clearance and neuronal support. Strategies that shift the balance toward DAM-like states could address a fundamental mechanism of disease progression rather than merely symptomatic relief. INPP5D inhibition offers a mechanism-based approach to achieve this reprogramming by enhancing the survival and metabolic fitness of microglia under the stressful conditions of the Alzheimer's brain. The presence of chronic neuronal damage, protein aggregation, and metabolic stress creates selective pressure against microglia that cannot sustain PI3K/AKT-mediated pro-survival signaling. By amplifying this pathway, INPP5D inhibition could enable microglia to maintain their protective functions despite ongoing pathological challenges. This approach is particularly attractive as a potential combination therapy with TREM2-activating antibodies, where dual intervention at the receptor level and the intracellular signaling level could produce additive or synergistic effects on microglial activation and function. Therapeutic Strategy Development of selective INPP5D inhibitors for Alzheimer's disease requires careful attention to CNS penetration, selectivity over related phosphatases, and therapeutic index. Small molecule INPP5D inhibitors based on scaffolds such as 3-mercapto-1,2,4-triazine derivatives have demonstrated activity in preclinical oncology models and could serve as starting points for optimization toward CNS exposure. Key considerations include achieving adequate brain penetration through balancing lipophilicity, minimizing P-glycoprotein efflux liability, and optimizing clearance properties for sustained CNS target engagement. Dosing strategies would need to balance efficacy in enhancing microglial PI3K/AKT signaling against potential immune-related adverse effects, with initial clinical studies likely focusing on safety, tolerability, and biomarker evidence of microglial modulation. Combination with TREM2 agonism represents a particularly compelling therapeutic strategy that could be tested in preclinical models before clinical development. The mechanistic rationale is straightforward: TREM2 engagement provides the upstream signal that generates PIP3, while INPP5D inhibition prevents signal dissipation. This combination could enable stronger and more sustained DAM commitment than either intervention alone, potentially allowing lower doses of each agent and thereby reducing individual compound-related risks. Potential Risks and Contraindications The absence of structured caution evidence in the current dataset requires careful consideration of potential risks based on INPP5D biology. INPP5D is expressed across multiple myeloid lineages including bone marrow-derived macrophages, and systemic immune cells are exposed to circulating drug following oral or parenteral administration. Complete blockade of INPP5D could theoretically dysregulate immune cell homeostasis, alter macrophage polarization in peripheral tissues, or impair responses to infection. The therapeutic index must be carefully characterized in toxicology studies, and patients with compromised immune function may require particular caution. Additionally, the PI3K/AKT pathway is a central regulator of cellular metabolism and survival in many tissue types, raising theoretical concerns about off-target effects in non-immune cells that express the target. From a patient selection standpoint, genetic variants in TREM2 that reduce receptor function could limit the efficacy of INPP5D inhibition if the upstream signal is insufficient to generate meaningful PIP3 accumulation. Patients homozygous for TREM2 loss-of-function variants, while rare, might derive minimal benefit from this mechanism. Biomarker strategies to identify patients with intact but insufficiently activated TREM2 signaling could improve therapeutic targeting. Future Directions The next critical steps for advancing INPP5D inhibition as an Alzheimer's therapeutic include detailed characterization of INPP5D expression and activity in human Alzheimer's brain tissue using single-nucleus RNA sequencing and proteomics approaches. These studies would establish whether INPP5D expression is upregulated in disease-relevant microglial subpopulations, suggesting compensatory feedback, or whether genetic variants that increase INPP5D activity contribute to disease risk. Development of CNS-penetrant, selective INPP5D inhibitors with favorable pharmaceutical properties is a prerequisite for clinical translation. Validating these compounds in mouse models of amyloid and tau pathology would establish in vivo efficacy, while large animal studies in non-human primates could address translatability concerns related to microglial biology differences between rodents and humans. Combination approaches with TREM2-targeted agents, immunomodulatory therapies, and anti-amyloid or anti-tau interventions warrant systematic exploration. Biomarker development including PET ligands for microglial activation states, CSF measures of lipid signaling intermediates, and peripheral immune markers would enable patient selection and monitoring in clinical trials. Ultimately, the genetic evidence linking INPP5D to Alzheimer's disease provides a compelling rationale for therapeutic targeting that justifies substantial investment in these future directions." Framed more explicitly, the hypothesis centers INPP5D within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating INPP5D or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.38, novelty 0.72, feasibility 0.22, impact 0.48, mechanistic plausibility 0.42, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `INPP5D` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of INPP5D or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Enrichment: 'Phosphatidylinositol metabolic process' (CSF1R, INPP5D, PLCG2; p=3.5e-06, odds ratio 142.4). This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. INPP5D genetically associated with AD through microglial signaling networks. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Modulates PI3K/AKT pathway downstream of multiple myeloid receptors. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammatory mediators and late-onset Alzheimer's disease risk factors. Identifier 41633359. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. SHIP-1 adapter functions mediate recruitment of FCRL1 to the BCR and inhibition of ERK. Identifier 41968726. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 expression in microglia during Alzheimer's disease progression. Identifier 41580850. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. INPP5D haploinsufficiency has not been validated as protective in AD models. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Emtricitabine (SHELL trial) was developed for ALS and was terminated; extrapolation to AD is speculative. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. The SHELL trial failed suggesting INPP5D inhibition may not be viable. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. PI3K/AKT signaling is tightly regulated; enhancing this pathway could promote microglial survival in ways that perpetuate neuroinflammation. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. INPP5D sits downstream of multiple myeloid receptors; global inhibition could amplify inflammatory signaling from TLRs and other receptors in harmful ways. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7389`, debate count `1`, citations `14`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates INPP5D in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "INPP5D (SHIP1) Inhibition to Shift Microglial Polarization". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting INPP5D within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers INPP5D within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating INPP5D or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.38, novelty 0.72, feasibility 0.22, impact 0.48, mechanistic plausibility 0.42, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `INPP5D` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of INPP5D or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Enrichment: 'Phosphatidylinositol metabolic process' (CSF1R, INPP5D, PLCG2; p=3.5e-06, odds ratio 142.4). This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

INPP5D genetically associated with AD through microglial signaling networks. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Modulates PI3K/AKT pathway downstream of multiple myeloid receptors. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammatory mediators and late-onset Alzheimer's disease risk factors. Identifier 41633359. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

SHIP-1 adapter functions mediate recruitment of FCRL1 to the BCR and inhibition of ERK. Identifier 41968726. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 expression in microglia during Alzheimer's disease progression. Identifier 41580850. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

INPP5D haploinsufficiency has not been validated as protective in AD models. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Emtricitabine (SHELL trial) was developed for ALS and was terminated; extrapolation to AD is speculative. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

The SHELL trial failed suggesting INPP5D inhibition may not be viable. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

PI3K/AKT signaling is tightly regulated; enhancing this pathway could promote microglial survival in ways that perpetuate neuroinflammation. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

INPP5D sits downstream of multiple myeloid receptors; global inhibition could amplify inflammatory signaling from TLRs and other receptors in harmful ways. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7389`, debate count `1`, citations `14`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates INPP5D in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "INPP5D (SHIP1) Inhibition to Shift Microglial Polarization".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting INPP5D within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["INPP5D
Hypothesis Target"]
    B["Synaptic
Cited Mechanism"]
    C["Cellular Response
Stress or Clearance Change"]
    D["Neural Circuit Effect
Synapse/Glia Vulnerability"]
    E["Alzheimer
Disease-Relevant Outcome"]
    A --> B
    B --> C
    C --> D
    D --> E
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for INPP5D from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

14 citations 5 with PMID Validation: 0% 8 supporting / 6 opposing

✓ For (8)

No supporting evidence

No opposing evidence

(6) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 9CLIN 2GENE 2EPID 1

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Enrichment: 'Phosphatidylinositol metabolic p…	Supporting	MECH	-	-	-	-	-	-
INPP5D genetically associated with AD through micr…	Supporting	GENE	-	-	-	-	-	-
Modulates PI3K/AKT pathway downstream of multiple …	Supporting	MECH	-	-	-	-	-	-
Repression of RIPK1 kinase by INPP5D inhibits expr…	Supporting	EPID	Immunity	-	2026	0.33	PMID:41633359	-
SHIP-1 adapter functions mediate recruitment of FC…	Supporting	MECH	Immunohorizons	-	2026	0.33	PMID:41968726	-
Single-cell sequencing analysis and machine learni…	Supporting	CLIN	J Transl Med	-	2026	0.33	PMID:41580850	-
PLCG2 signaling and genetic resilience in Alzheime…	Supporting	GENE	Mol Neurodegene…	-	2026	0.49	PMID:41888907	-
INPP5D/SHIP1-mediated immunometabolic remodeling o…	Supporting	MECH	Front Immunol	-	2026	0.33	PMID:41853261	-
INPP5D haploinsufficiency has not been validated a…	Opposing	MECH	-	-	-	-	-	-
Emtricitabine (SHELL trial) was developed for ALS …	Opposing	MECH	-	-	-	-	-	-
The SHELL trial failed suggesting INPP5D inhibitio…	Opposing	MECH	-	-	-	-	-	-
PI3K/AKT signaling is tightly regulated; enhancing…	Opposing	CLIN	-	-	-	-	-	-
INPP5D sits downstream of multiple myeloid recepto…	Opposing	MECH	-	-	-	-	-	-
Limited direct evidence that INPP5D inhibition wou…	Opposing	MECH	-	-	-	-	-	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 8

Enrichment: 'Phosphatidylinositol metabolic process' (CSF1R, INPP5D, PLCG2; p=3.5e-06, odds ratio 142.4)

INPP5D genetically associated with AD through microglial signaling networks

Modulates PI3K/AKT pathway downstream of multiple myeloid receptors

Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammatory mediators and late-onset A…▼

Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammatory mediators and late-onset Alzheimer's disease risk factors.

Immunity · 2026 · PMID:41633359 · Q:0.33

SHIP-1 adapter functions mediate recruitment of FCRL1 to the BCR and inhibition of ERK.

Immunohorizons · 2026 · PMID:41968726 · Q:0.33

Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 expression in microglia durin…▼

Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 expression in microglia during Alzheimer's disease progression.

J Transl Med · 2026 · PMID:41580850 · Q:0.33

PLCG2 signaling and genetic resilience in Alzheimer's disease.

Mol Neurodegener · 2026 · PMID:41888907 · Q:0.49

INPP5D/SHIP1-mediated immunometabolic remodeling of renal monocytes in idiopathic membranous nephropathy.

Front Immunol · 2026 · PMID:41853261 · Q:0.33

✗ Opposing Evidence 6

INPP5D haploinsufficiency has not been validated as protective in AD models

Emtricitabine (SHELL trial) was developed for ALS and was terminated; extrapolation to AD is speculative

The SHELL trial failed suggesting INPP5D inhibition may not be viable

PI3K/AKT signaling is tightly regulated; enhancing this pathway could promote microglial survival in ways that…▼

PI3K/AKT signaling is tightly regulated; enhancing this pathway could promote microglial survival in ways that perpetuate neuroinflammation

INPP5D sits downstream of multiple myeloid receptors; global inhibition could amplify inflammatory signaling f…▼

INPP5D sits downstream of multiple myeloid receptors; global inhibition could amplify inflammatory signaling from TLRs and other receptors in harmful ways

Limited direct evidence that INPP5D inhibition would amplify TREM2-specific signals in microglia

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Hypothesis Debate | 4 rounds | 2026-04-26 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Theoretical Analysis: PLCG2 Allosteric Modulation for TREM2-Dependent Microglial Dysfunction

Molecular Mechanisms

The TREM2-PLCG2 axis represents a critical signaling node in microglial biology. TREM2 engagement activates SYK kinase (PMID: 28642471), which phosphorylates and recruits PLCG2 to the membrane. PLCG2 hydrolysis of PIP2 generates IP3 (elevating cytosolic Ca²⁺) and DAG (activating PKC isoforms), initiating downstream transcriptional programs essential for microglial metabolic fitness and survival under neurodegenerative stress.

In Alzheimer's disease, TREM2 loss-of-function

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation

Key Weaknesses

Unproven compensatory bypass: The core therapeutic premise—that enhanced PLCG2 activity can compensate for TREM2 loss-of-function—lacks direct experimental support. TREM2 engages multiple downstream pathways beyond PLCG2 (including SYK-dependent transcriptional programs with broad cellular consequences). Artificially amplifying PLCG2 flux may not recapitulate the physiological signal integration TREM2 normally provides, potentially producing qualitatively different cellular states.

Specificity paradox: The analysis proposes allosteric modu

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Expert Assessment: PLCG2 Allosteric Modulation for TREM2-Dependent Microglial Dysfunction

Druggability

PLCG2 is a large enzyme (~1300 aa) with multiple regulatory domains (SH3-SH2-PLCγc), making allosteric targeting mechanistically feasible in principle. The existence of activating point mutations (e.g., P522R) validates that PLCG2 catalytic output can be therapeutically modulated without obliteration of the protein. However, a critical challenge is achieving selectivity over PLCG1 (~70% homology), which is broadly expressed and essential. The field lacks validated small-molecule al

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{"hypothesis_title": "PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction", "synthesis_summary": "This hypothesis proposes targeting PLCG2 allosterically to compensate for TREM2 loss-of-function in Alzheimer's disease, leveraging the established TREM2-PLCG2-SYK signaling axis. While the mechanistic rationale is supported by genetic variants linking TREM2 to AD risk, critical gaps remain in demonstrating that isolated PLCG2 enhancement can functionally bypass the broader signaling disruption caused by TREM2 dysfunction. The approach faces substant

Price History

7d Trend

↘

Falling

7d Momentum

▼ 7.3%

Volatility

High

0.1655

Events (7d)

⚡ Price Movement Log Recent 9 events

	Event	Price	Change	Source	Time
📊	Score Update	$0.545	▼ 13.3%	market_dynamics	2026-04-17 08:24
📊	Score Update	$0.628	▲ 33.0%	market_dynamics	2026-04-17 05:24
📄	New Evidence	$0.472	▼ 27.9%	market_dynamics	2026-04-17 05:04
💬	Debate Round	$0.655	▲ 28.2%	market_dynamics	2026-04-17 02:24
💬	Debate Round	$0.510	▼ 18.0%	market_dynamics	2026-04-17 02:12
📄	New Evidence	$0.623	▲ 35.7%	market_dynamics	2026-04-17 01:18
💬	Debate Round	$0.459	▼ 21.9%	market_dynamics	2026-04-16 23:55
📄	New Evidence	$0.587	▲ 30.4%	market_dynamics	2026-04-16 22:35
📊	Score Update	$0.451		market_dynamics	2026-04-16 21:14

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (5)

Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 expression in microglia during Alzheimer's disease progression.

Journal of translational medicine (2026) · PMID:41580850

No extracted figures yet

Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammatory mediators and late-onset Alzheimer's disease risk factors.

Immunity (2026) · PMID:41633359

No extracted figures yet

INPP5D/SHIP1-mediated immunometabolic remodeling of renal monocytes in idiopathic membranous nephropathy.

Front Immunol (2026) · PMID:41853261

No extracted figures yet

PLCG2 signaling and genetic resilience in Alzheimer's disease.

Mol Neurodegener (2026) · PMID:41888907

No extracted figures yet

SHIP-1 adapter functions mediate recruitment of FCRL1 to the BCR and inhibition of ERK.

Immunohorizons (2026) · PMID:41968726

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (5)

📓 SciDEX Analysis: 2026 04 01 Gap 001

Computational notebook for SDA-2026-04-01-gap-001

📓 Top 5 Analysis: Sda 2026 04 01 Gap 001

Computational notebook for SDA-2026-04-01-gap-001

📓 TREM2 agonism vs antagonism in DAM microglia - Rich Analysis

TREM2/DAM analysis with expression plots, pathway enrichment, hypothesis scoring

📓 TREM2 agonism vs antagonism in DAM microglia

Analysis ID: SDA-2026-04-01-gap-001 Date: 2026-04-01 Domain: neurodegeneration Key Hypotheses: - TREM2-Dependent Microglial Senescence Transition (score: 0.705) - Cell-Type Specific TREM …

📓 TREM2 agonism vs antagonism in DAM microglia — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-01-gap-001. The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score

1.00

80.4th percentile (776 hypotheses)

Tokens Used

KG Edges Generated

398

Citations Produced

Cost Ratios

Cost per KG Edge

1.29 tokens

Lower is better (baseline: 2000)

Cost per Citation

4.44 tokens

Lower is better (baseline: 1000)

Cost per Score Point

60.79 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.100

10% weight of efficiency score

Adjusted Composite

0.858

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-17T09:10	$0.741	0.580

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for INPP5D.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for INPP5D →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (58)

5xFAD/PS19 mouse models APOE APOE4 dysfunction ARIA ARIA risk Amyloid PET Centiloid CSF p-tau181 CSF sTREM2 CSF1R CSF1R-TREM2 CX3CR1 CX3CR1-TREM2 DAM DAM transition DAM1 microglial state DAP12 DAP12-PI3K-AKT pathway INPP5D PLCG2 SHIP1

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.907 | neurodegeneration

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.895 | neurodegeneration

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration

Score: 0.892 | neurodegeneration

Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration

Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF primary microglia or iPSC-derived microglia are treated with selective INPP5D (SHIP1) inhibitor THEN AKT phosphorylation (T308 and S473) will increase and Disease-Associated Microglia (DAM) signature gene expression (Apoe, Lpl, Clec7a, Itgax) will be upregulated compared to vehicle control

pending conf: 0.50

Expected outcome: Significant increase in AKT phosphorylation levels (p-AKT T308 and S473) measured by Western blot or phospho-flow cytometry, and elevated mRNA/protein expression of DAM transcriptional markers (APOE, LPL, CLEC7A, ITGAX) measured by RT-qPCR, ELISA, or flow cytometry in INPP5D-inhibited microglia

Falsified by: INPP5D inhibition does NOT significantly increase AKT phosphorylation or DAM gene expression above baseline; instead, phosphorylation and gene expression remain unchanged or decrease, disproving the hypothesis that INPP5D negatively regulates PI3K/AKT signaling in microglia

Method: Primary mouse microglia or iPSC-derived human microglia treated with selective INPP5D inhibitor (e.g., pelabresib) or vehicle for 24-48 hours. Outcome measures: (1) AKT phosphorylation by immunoblotting, (2) DAM gene expression by RNA-seq or RT-qPCR, (3) flow cytometry for cell surface DAM markers

IF microglia receive combined TREM2 agonism plus INPP5D inhibition THEN synergistic enhancement of DAM transcriptional program and phagocytic activity will be observed relative to either treatment alone using mouse primary microglia or iPSC-derived microglia

pending conf: 0.50

Expected outcome: Combined TREM2 agonist + INPP5D inhibitor treatment will produce significantly greater upregulation of DAM genes (Apoe, Lpl, Clec7a, Itgax) and enhanced phagocytic activity (measured by uptake of fluorescently-labeled prey particles or myelin debris) compared to TREM2 agonism alone, INPP5D inhibition alone, or vehicle control

Falsified by: Combined TREM2 agonism + INPP5D inhibition does NOT produce synergistic or additive enhancement of DAM markers; if the effect size equals or is less than single treatments, the hypothesis that these pathways converge on PI3K/AKT to drive DAM programming is disproven

Method: Primary microglia or iPSC-derived microglia treated with: (1) TREM2 agonist antibody alone, (2) INPP5D inhibitor alone, (3) combination of both, or (4) vehicle. Measure: (1) DAM gene expression by RNA-seq/RT-qPCR, (2) phagocytosis of fluorescent E. coli or myelin debris by flow cytometry or live imaging, (3) AKT pathway activation

Knowledge Subgraph (43 edges)

activates (3)

TREM2→DAP12-PI3K-AKT pathwayTREM2→DAM1 microglial stateTREM2 agonism→amyloid clearance

associated with (8)

PLCG2→neurodegenerationTREM2-APOE axis→neurodegenerationCSF1R-TREM2→neurodegenerationTREM2-mTOR pathway→neurodegenerationCX3CR1-TREM2→neurodegeneration

▸ Show 3 more

INPP5D→neurodegenerationARIA→accelerated amyloid clearance5xFAD/PS19 mouse models→human disease trajectory

▸ Show 5 more

TYROBP→DAP12TREM2-mTOR pathway→TREM2CX3CR1-TREM2→CX3CR1CX3CR1-TREM2→TREM2INPP5D→SHIP1

inhibits (1)

TREM2 R47H variant→DAM transition

modulates (2)

APOE4 dysfunction→TREM2 dysfunctionbiased PI3K agonism→TREM2-DAP12 signalosome

prevents (1)

TREM2 antagonism→late-stage tauopathy neuroinflammation

protective against (1)

Soluble TREM2→ARIA risk

regulates (1)

TREM2-APOE4 axis→lipid metabolism dysfunction

targets (7)

h-39148342→INPP5Dh-0f025d94→PLCG2h-5b378bd3→TREM2-APOE axish-7597968b→CX3CR1-TREM2h-0cbe9bac→CSF1R-TREM2

▸ Show 2 more

h-2e03f316→TREM2-mTOR pathwayh-f503b337→TYROBP

therapeutic target for (1)

Stage-selective TREM2 agonism→early amyloid phase Alzheimer's disease

Mechanism Pathway for INPP5D

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_39148342["h-39148342"] -->|targets| INPP5D["INPP5D"]
    INPP5D_1["INPP5D"] -->|associated with| neurodegeneration["neurodegeneration"]
    INPP5D_2["INPP5D"] -->|co associated with| SHIP1["SHIP1"]
    style h_39148342 fill:#4fc3f7,stroke:#333,color:#000
    style INPP5D fill:#ce93d8,stroke:#333,color:#000
    style INPP5D_1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style INPP5D_2 fill:#ce93d8,stroke:#333,color:#000
    style SHIP1 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 INPP5D — PDB 2YSQ Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

TREM2 agonism vs antagonism in DAM microglia

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

TREM2-APOE Axis Dissociation for Selective DAM Activation

Score: 0.89 · TREM2-APOE axis

CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion

Score: 0.81 · CSF1R-TREM2

TREM2-mTOR Co-Agonism for Metabolic Reprogramming

Score: 0.80 · TREM2-mTOR pathway

CX3CR1-TREM2 Integration for Synapse Pruning Normalization

Score: 0.78 · CX3CR1-TREM2

PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Depen

Score: 0.53 · PLCG2

→ View all analysis hypotheses

INPP5D (SHIP1) Inhibition to Shift Microglial Polarization

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 8

✗ Opposing Evidence 6

Theoretical Analysis: PLCG2 Allosteric Modulation for TREM2-Dependent Microglial Dysfunction

Molecular Mechanisms

Critical Evaluation

Key Weaknesses

Expert Assessment: PLCG2 Allosteric Modulation for TREM2-Dependent Microglial Dysfunction

Druggability

Price History

Clinical Trials (0)

📚 Cited Papers (5)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (5)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (58)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (43 edges)

activates (3)

associated with (8)

biomarker for (4)

causal extracted (1)

causes (3)

co associated with (10)

inhibits (1)

modulates (2)

prevents (1)

protective against (1)

regulates (1)

targets (7)

therapeutic target for (1)

Mechanism Pathway for INPP5D

3D Protein Structure

Source Analysis

TREM2 agonism vs antagonism in DAM microglia

Community Feedback

Same Analysis (5)